##plugins.themes.academic_pro.article.main##
Abstract
Progress in the treatment of this disease, metastatic dissemination is still considered an inclusive condition. In this lecture will be considered questions of «non-standard» therapy, which may be included in our practice in the future
Keywords
Metastatic Breast Cancer
High-Dose Chemotherapy
Metronome Therapy
##plugins.themes.academic_pro.article.details##
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Umida Ismailova Abdullayevna, Atahanova Nigora Ergashevna, Kurbankulov Uktam Muhammadovich, & Jumanazarov Azizbek Ulugbekovich. (2024). APPROACHES TO THE TREATMENT OF METASTATIC BREAST CANCER. Texas Journal of Medical Science, 33, 46–51. https://doi.org/10.62480/tjms.2024.vol33.pp46-51
References
- Frei E., Antman K., Teicher B. et al. Bone marrow autotransplantation for solid tumors-prospects // Journal of Clinical Oncology. – 1989. – Vol. 7. – № 4. – P. 515–526.
- Williams S.F. Is there a role for dose-intensive chemotherapy with stem cell rescue in breast cancer? // Oncology (Williston Park, N.Y.). – 2002. – Vol. 16. – № 12. – P. 1643–1646.
- Tartarone A., Romano G., Galasso R. et al. Should we continue to study high-dose chemotherapy in metastatic breast cancer patients? A critical review of the published data // Bone Marrow Transplantation. – 2003. – Vol. 31. – № 7. – P. 525–530.
- Gutierrez-Delgado F., Holmberg L.A., Hooper H. et al. High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer // Bone Marrow Transplantation. – 2000. – Vol. 26. – № 1. – P. 51–59.
- Gratwohl A., Baldomero H., Rosti G. High-dose chemotherapy for breast cancer // Bone Marrow Transplantation. – 2000. – Vol. 26. – № 6. – P. 599.
- Borges V.F., Elias A.D. The era of high-dose chemotherapy for breast cancer: revisiting a troubled quest // Journal of Clinical Oncology. – 2011. – Vol. 29. – № 24. – P. 3205–3206.
- Ueno N.T., Rondón G., Mirza N.Q. et al. Allogeneic peripheral-blood progenitor-cell transplantation for poorrisk patients with metastatic breast cancer // Journal of Clinical Oncology. – 1998. – Vol. 16. – № 3. – P. 986–993.
- Boudin L., Gonçalves A., Sabatier R. et al. Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation // Bone Marrow Transplantation. – 2016 – Vol. 51. – № 8 – P. 1082–1086.
- Shaked Y., Emmenegger U., Man S. et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity // Blood. – 2005. – Vol. 106. – № 9. – P. 3058–3061.
- Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy // Nature Reviews Cancer. – 2004. – Vol. 4. – № 6. – P. 423-436.
- Gennari A., Stockler M., Puntoni M. et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials // Journal of Clinical Oncology. – 2011. – Vol. 29. – № 16 – P. 2144–2149.
- Dirix L.Y., Van Dam P.A., Prove A.M. et al. Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed? // Therapeutic Advances in Medical Oncology. – 2010. – Vol. 2. – № 5. – P. 331–342.
- Banys-Paluchowski М., Schütz F., Ruckhäberle E. et al. Metronomic Chemotherapy for Metastatic Breast Cancer – A Systematic Review of the Literature // Geburtshilfe Frauenheilkd. – 2016 – Vol. 76. – № 5. – P. 525–534.
- Disis M.L., Stanton S.E. Immunotherapy in breast cancer: an introduction // The Breast. – 2017. – Vol. 3. – № 17. – P. 30013–30019.
- Katayama H., Boldt C., Ladd J.J. et al. An autoimmune response signature associated with the development of triple-negative breast cancer reflects disease pathogenesis // Cancer Research. – 2015. – Vol. 75. – № 16. – P. 3246–3254.
- Gallo S., Sanqiolo D., Carnevale Schianca F. et al. Treating breast cancer with cell-based approaches: an overview // Expert option on biological therapy. – 2017. – Vol. 17. – № 10. – P. 1255–1264.
- Hendrickx W., Simeone I., Anjum S. et al. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis // Oncoimmunology. – 2017. – Vol. 6. – № 2. – e. 253654.
- Nanda R., Chow L.Q., Dees E.C. et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study // Journal of Clinical Oncology. – 2016. – Vol. 34. – № 21. – P. 2460–2467.
- Khosravi-Shahi P., Cabezón-Gutiérrez L., Custodio-Cabello S. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies // Asia-Pacific Journal of Clinical Oncology. – 2017. – Vol. 16. – Suppl. 1. [Epub ahead of print].
- Borges V.F., Elias A.D. The era of high-dose chemotherapy for breast cancer: revisiting a troubled quest // Journal of Clinical Oncology. – 2011. – Vol. 29. – № 24. – P. 3205–3206.
- Clifton G.T., Peoples G.E., Mittendorf E.A. The development and use of the E75 (HER2 369-377) peptide vaccine // Future Oncology. – 2016. – Vol. 12. – № 11. – P. 1321–1329.
- Gates J.D., Clifton G.T., Benavides L.C. et al. Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide // Vaccine. – 2010. – Vol. 28. – № 47. – P. 7476–7482.
- Disis M.L., Pupa S.M., Gralow J.R. et al. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer // Journal of Clinical Oncology. – 1997. – Vol. 15. – № 11. – P. 3363–3367.
- Emens L.A. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade // Expert Review gf Anticancer Therapy. – 2012. – Vol. 12. – № 12. – P. 1597–1611.
- Bardia A., Mayer I.A., Diamond J.R. et al. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients with Metastatic Triple-Negative Breast Cancer // Journal of Clinical Oncology. – 2017. – Vol. 35. – № 19. – P. 2141–2148.
- Baselga J., Im S.A., Iwata H. et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial // Lancet Oncology. – 2017 – Vol. 18. – № 7. – P. 904–916. А.С. Жабина Т. 18, №3 – 2017 273
- Koh M.Y., Spivak-Kroizman T., Venturini S. et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha // Molecular cancer therapeutics. – 2008. – Vol. 7. – № 1. – P. 90–100.